Press

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings

Oct 10 • 3 min read

Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces that it has completed its admission to the Access segment of the AQSE Growth…

Origin Therapeutics Announces Results of Annual General and Special Meeting of Shareholders

Oct 10 • 2 min read

Origin Therapeutics Holdings Inc. (the “Company” or “Origin”) (CSE: ORIG) is pleased to announce that, in connection with the proposed business combination transaction (the “Transaction”) with Safe Supply Streaming Co Ltd. (“Safe Supply”), all matters submitted to shareholders for approval as set out in detail in the Company’s management information circular dated August 1, 2023…

Safe Supply and Origin Therapeutics Receive Conditional Approval for Listing On the CSE

Oct 10 • 2 min read

Safe Supply Streaming Co. Ltd. (“Safe Supply” or the “Company”) and Origin Therapeutics Holdings Inc. (“Origin”) (CSE: ORIG) are pleased to announce that they have received conditional approval to list Safe Supply’s common shares on the Canadian Securities Exchange (the “CSE”). Final approval and trading of the Company shares are subject to fulfilling customary CSE requirements….

Medicinal Mushroom Market Anticipated to Reach USD 62.0 Bn by 2032 with 8.7% CAGR | Analysis by Marketresearch.biz

Oct 9 • 11 min read

Rising demand for medicinal mushrooms, like reishi, cordyceps, lion’s mane, and chaga, is fueled by their delightful taste and health benefits. They’re becoming popular ingredients in various foods and drinks due to their unique flavors. Global Medicinal Mushroom Market witnessed a valuation of USD 27.5 Bn in 2022 and is anticipated to reach USD 62.0 Bn by 2032, exhibiting a CAGR of…

Atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

Oct 9 • 2 min read

atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023. Details of the company’s participation is as follows: Jefferies Inaugural Biotech CNS/Neuro Summit Format: Fireside Chat Date and Time: Wednesday, October 11th at…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441